This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Johns Hopkins University. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: Innovations of Yingjun Li in Antifungal and Antitumor Research
Introduction
Yingjun Li is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of itraconazole analogs. With a total of 3 patents, his work focuses on enhancing the therapeutic potential of existing antifungal drugs.
Latest Patents
One of Yingjun Li's latest patents is centered around itraconazole analogs and their use. Itraconazole is a widely used antifungal drug known for its potent anti-angiogenic and anti-hedgehog activities. These properties have shown promising antitumor activity in several human clinical studies. However, the broader application of itraconazole in cancer treatment has been hindered by its strong inhibition of the drug metabolic enzyme CYP3A4, leading to potential drug-drug interactions. To address this issue, Yingjun Li synthesized a series of itraconazole derivatives aimed at eliminating CYP3A4 inhibition while retaining the drug's anti-angiogenic activity. The newly synthesized analogs were evaluated for their cytotoxicity against human umbilical vein endothelial cells (HUVEC) and their inhibitory activity against the CYP3A4 enzyme.
Career Highlights
Yingjun Li is affiliated with Johns Hopkins University, where he conducts his research and development work. His innovative approach to drug design has positioned him as a key figure in the pharmaceutical research community.
Collaborations
Yingjun Li has collaborated with notable colleagues such as Wukun Liu and Wei Shi. Their combined expertise has contributed to the advancement of research in the field of drug development.
Conclusion
Yingjun Li's work in synthesizing itraconazole analogs represents a significant advancement in the treatment of fungal infections and cancer. His innovative research continues to pave the way for new therapeutic options in medicine.